ERCC1-Specific Immunostaining in Non–Small-Cell Lung Cancer

Authors:

Abstract
In their letter to the editor, Niedernhofer et al. (June 14 issue)1 have doubts about the specificity of the monoclonal mouse antibody 8F1, which is used to detect the excision repair cross-complementation group 1 (ERCC1) protein. These doubts are important to reconcile, because two studies have reported that high levels of ERCC1 expression, as detected by means of immunohistochemical staining of primary tumors with the use of the 8F1 monoclonal antibody, are associated with a good prognosis in non–small-cell lung cancer yet negatively affect the response to chemotherapeutic agents.2,3 Hence, the expression level of the epitope recognized by 8F1 (presumably ERCC1) may influence the management of non–small-cell lung cancer.